Date: 2016-11-14
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Society for Immunotherapy of Cancer Annual Meeting (SITC)
Company: Celldex Therapeutics (USA - NJ)
Product: CDX-1140
Action
mechanism: monoclonal antibody.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On November 14, 2016, Celldex Therapeutics presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist activity. Found on antigen presenting cells, such as dendritic cells, macrophages and B cells, CD40 is a key activator of the immune response. The data were presented at the Society for Immunotherapy of Cancer Annual Meeting (SITC) on Saturday, November 12 in a poster titled "Functional characterization of CDX-1140, a novel CD40 antibody agonist for cancer immunotherapy." CDX-1140 is expected to be ready to enter clinical studies in 2017. Key findings include: CDX-1140 binds CD40 with high affinity and specificity and does not block CD40 ligand binding
CDX-1140 has an unmodified IgG2 backbone and demonstrates potent agonist activity independent of Fc receptor interactions
CDX-1140 demonstrates direct anti-tumor activity in immune-deficient mice challenged with human lymphomas
Pharmacological activity was observed in vivo with minimal evidence of toxicity
Celldex is currently performing manufacturing and IND-enabling studies to support Phase 1 dose-escalation studies. The Company believes that the potential for CDX-1140 will be best defined in combination studies with other immunotherapies or conventional cancer treatments.
